We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $604M
1-Year Est. Return 96.57%
This Fund
S&P 500
This Quarter Est. Return
-5.88%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$315M
AUM Growth
+$48.5M
Cap. Flow
-$4.73M
Cap. Flow %
-1.5%
Top 10 Hldgs %
69.9%
Holding
69
New
7
Increased
7
Reduced
7
Closed
20
Avg Time Held Equity + Options
4 quarters
Top 10 Avg Time Held Equity + Options
1.5 quarters
Top 20 Avg Time Held Equity + Options
1.7 quarters
Avg Time Held Equity only
4.4 quarters
Top 10 Avg Time Held Equity only
2.2 quarters
Top 20 Avg Time Held Equity only
1.7 quarters

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$30M
2
SNY icon
Sanofi
SNY
+$15.9M
3
COR icon
Cencora
COR
+$14.2M
4
SNN icon
Smith & Nephew
SNN
+$5.85M
5
SKIN icon
SkinHealth Systems
SKIN
+$3.75M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$10.4M
2
BIIB icon
Biogen
BIIB
+$7.32M
3
MDT icon
Medtronic
MDT
+$7.18M
4
SGHT icon
Sight Sciences
SGHT
+$6.52M
5
NTUS
Natus Medical Inc
NTUS
+$6.26M

Sector Composition

Rank Sector Weight
1 Healthcare 63.89%
2 Miscellaneous 26.34%
3 Financials 7.31%
4 Consumer Staples 2.47%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
COR icon
1
Cencora
COR
$63B
$38.2M 12.14%
282,399
+99,065
+54% +$14.2M
2021 Q4
3 quarters
APLS icon
2
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$34.7M 11.02%
+507,700
New +$30M
2022 Q3
0 quarters
GSK icon
3
GSK
GSK
$92.7B
$23.3M 7.39%
+790,600
New +$30M
2022 Q3
0 quarters
MSAC
4
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$23M 7.31%
2,323,000
– –
2021 Q4
3 quarters
RLMD icon
5
PUT
Relmada Therapeutics
RLMD
$358M
$22.4M 7.13%
+606,200
New +$16.8M
2022 Q3
0 quarters
RXDX
6
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$19.6M 6.23%
332,200
+230,600
+227% +$10.6M
2022 Q2
1 quarter
BCYC icon
7
Bicycle Therapeutics
BCYC
$254M
$15.9M 5.05%
683,425
-5,564
-0.8% -$132K
2021 Q4
3 quarters
OGN icon
8
Organon & Co
OGN
$3.62B
$14.7M 4.68%
628,836
+53,981
+9% +$1.63M
2022 Q2
1 quarter
CI icon
9
Cigna
CI
$74.7B
$14.6M 4.64%
52,611
-423
-0.8% -$119K
2020 Q3
8 quarters
SNY icon
10
Sanofi
SNY
$93.7B
$13.6M 4.31%
+356,888
New +$15.9M
2022 Q3
0 quarters
INGN icon
11
Inogen
INGN
$168M
$12.7M 4.02%
521,295
-4,143
-0.8% -$114K
2021 Q4
3 quarters
CNC icon
12
Centene
CNC
$34B
$9.88M 3.14%
127,011
-2,000
-2% -$179K
2021 Q1
6 quarters
UTHR icon
13
United Therapeutics
UTHR
$23.3B
$9.41M 2.99%
44,959
+5,000
+13% +$1.12M
2018 Q4
15 quarters
SKIN icon
14
SkinHealth Systems
SKIN
$1.41B
$7.77M 2.47%
32,948
+14,833
+82% +$3.75M
2022 Q2
1 quarter
SNN icon
15
Smith & Nephew
SNN
$11.7B
$5.3M 1.69%
+228,390
New +$5.85M
2022 Q3
0 quarters
VNDA icon
16
Vanda Pharmaceuticals
VNDA
$260M
$4.83M 1.54%
488,965
– –
2022 Q1
2 quarters
PNT
17
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$4.21M 1.34%
544,545
+40,000
+8% +$340K
2021 Q4
3 quarters
NARI icon
18
DELISTED
Inari Medical, Inc. Common Stock
NARI
$4.17M 1.33%
57,466
-55,000
-49% -$4.09M
2022 Q1
2 quarters
UHS icon
19
Universal Health Services
UHS
$10.6B
$3.59M 1.14%
40,725
– –
2022 Q2
1 quarter
EUCRU
20
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.49M 0.79%
248,674
– –
2020 Q4
7 quarters
OBIO icon
21
Orchestra BioMed
OBIO
$344M
$2.48M 0.79%
250,000
– –
2020 Q3
8 quarters
SYRE icon
22
Spyre Therapeutics
SYRE
$7.52B
$2.46M 0.78%
186,741
– –
2020 Q2
9 quarters
XFOR icon
23
X4 Pharmaceuticals
XFOR
$258M
$2.43M 0.77%
47,282
+38,052
+412% +$1.31M
2021 Q1
6 quarters
MODD icon
24
Modular Medical
MODD
$17.4M
$2.37M 0.75%
19,145
– –
2022 Q2
1 quarter
CBAY icon
25
DELISTED
Cymabay Therapeutics
CBAY
$1.95M 0.62%
555,610
– –
2020 Q1
10 quarters
1
2 3

Similar funds

EFL
ERn Financial LLC Middleton, Wisconsin $604M AUM 19.83% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Sio Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Sio Capital Management held 69 positions worth $315M, up 18% from $266M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sio Capital Management's Q3 2022 filing shows 7 new, 7 increased, 7 reduced and 20 closed positions. Its largest new stake was GSK: 790,600 shares worth $23.3M. The largest sale was HCA Healthcare, an estimated $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Financials.

  • Sio Capital Management's largest Q3 2022 buy was GSK: 790,600 shares worth $23.3M.
  • Sio Capital Management added most to Cencora in Q3 2022, an estimated $14.2M increase.
  • Sio Capital Management's biggest Q3 2022 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $4.09M.
  • Sio Capital Management fully exited HCA Healthcare in Q3 2022, selling an estimated $10.4M.
  • Sio Capital Management's ten largest holdings make up 70% of its $315M portfolio in Q3 2022.
  • Sio Capital Management opened 7 new positions and closed 20 in Q3 2022.
  • Sio Capital Management's portfolio value rose 18% quarter-over-quarter to $315M.

Based on Sio Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.